This trial tests if adding certolizumab to usual treatment can improve pregnancy outcomes in women with APS and LAC. Certolizumab reduces inflammation, which may help improve blood flow to the placenta and lead to better pregnancy results. Certolizumab pegol has been identified as a promising treatment during pregnancy because it has no late active placental transfer and no clear signs of fetal harm.